S-1/A: Picard Medical Files for IPO Amidst Significant Losses and Going Concern Doubts, Eyes Global Expansion for Artificial Heart Technology

Picard Medical, Inc., developer of the only FDA-approved total artificial heart, is seeking to raise $15.4 million in its initial public offering on the NYSE American, despite a history of substantial net losses and an auditor's warning about its ability to continue as a going concern.

Summary

• Picard Medical, Inc. is a holding company that owns SynCardia Systems, LLC, which manufactures and sells the only U.S. FDA and Health Canada approved implantable total artificial heart (SynCardia TAH).
• The company is offering 4,250,000 shares of common stock in its initial public offering (IPO) at an estimated price range of $3.50 to $4.50 per share, with a midpoint of $4.00, aiming to raise approximately $15.4 million in net proceeds after deducting estimated underwriting discounts and offering expenses.
• Proceeds from the IPO are intended to fund market expansion in China via a joint venture ($2.85 million), research and development activities for new products ($4.05 million), satisfy working capital related party loans (approximately $2.0 million), repay Senior Secured Notes (up to $6.0 million), and build sales, marketing, and distribution capabilities (approximately $0.5 million).
• Picard Medical has incurred significant net losses, including $15.6 million for the year ended December 31, 2023, $21.1 million for the year ended December 31, 2024, and $5.6 million for the three months ended March 31, 2025.
• The company's total revenues decreased by 13% from $5.043 million in 2023 to $4.391 million in 2024, and by 69% from $1.980 million in Q1 2024 to $0.620 million in Q1 2025.
• As of March 31, 2025, the company had a working capital deficit of $30.435 million and total liabilities of $40.620 million, with an accumulated deficit of $55.4 million.
• The auditor's report includes an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern.
• The SynCardia TAH has been implanted in over 2,100 patients across 27 countries and is an established bridge to heart transplantation (BTT) for patients with biventricular failure.
• The company is developing a fully implantable total artificial heart, 'Emperor', with animal studies planned for the second half of 2025 and potential FDA approval by 2028.
• Picard Medical is also working on expanding the SynCardia TAH's indications for use to include Bridge to Candidacy (BTC) and long-term use (2 years or more), with an FDA answer expected in Q2 2026 for the BTC and imminent death removal submission.
• An upgraded portable driver system, 'Freedom+', is under FDA review with approval anticipated by the second half of 2025, expected to reduce false alarm rates and servicing costs.
• The company voluntarily cancelled its EU CE mark in July 2022 due to post-market surveillance deficiencies under the MDD and plans to reapply for an MDR CE mark in Q4 2025.
• 104 reports of cannula tears have been received as of March 20, 2025, with zero reported Serious Adverse Events; a design change is expected to be submitted to the FDA in Q3 2025.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, evidenced by substantial and increasing net losses, a significant working capital deficit, and an explicit 'going concern' warning from its auditor. While the core product (SynCardia TAH) is FDA-approved and has a strong clinical track record, and there are promising R&D initiatives, the current financial instability and reliance on future capital raises present a very high risk profile. The loss of the EU CE mark and delays in re-certification further compound the challenges. The positive aspects of the technology are heavily overshadowed by the precarious financial health.

Positives

• Picard Medical manufactures and sells the only U.S. FDA and Health Canada approved implantable total artificial heart (SynCardia TAH).
• Over 2,100 SynCardia TAHs have been implanted in patients across 27 countries, demonstrating extensive clinical experience and an established presence.
• The SynCardia TAH is an established bridge to heart transplantation (BTT) for patients with biventricular failure.
• The company is actively pursuing new product developments, including the fully implantable 'Emperor' TAH and upgraded portable drivers ('Freedom+').
• The SynCardia TAH implant procedures are approved by CMS under DRG 001, the highest possible reimbursement, with payments ranging from $193,000 to $469,000.
• Hospitals have reported success in securing reimbursement from many private insurance carriers including Aetna, Cigna, Anthem, United Health, and Humana.
• Clinical studies show strong efficacy, with 79% survival to transplantation for SynCardia TAH patients compared to 46% for controls, and 1-year post-transplant survival rates of 86%.
• Real-world data (RWD) confirms high 1-year survival rates (75% to 86.6%) for SynCardia TAH patients.
• Neurological events in RWD for SynCardia TAH patients are relatively low (5% of total adverse events) compared to initial PMA study data.
• The company holds six awarded U.S. and international patents and has more than twelve pending, including new patents for its next-generation total artificial heart technology.
• Picard Medical maintains an ISO 13485-certified quality management system and successfully completed its latest MDSAP audit in November 2024 with no deficiencies.
• A key competitor, Carmat SA, filed for insolvency with the French commercial court on June 30, 2025, potentially reducing competition in the TAH market.
• The FDA approved the removal of 'temporary' and '-t' from the SynCardia TAH Indications for Use (IFU) and product name on November 25, 2024, broadening its potential application.

Negatives

• The company has a history of significant net losses, including $15.6 million in 2023, $21.1 million in 2024, and $5.6 million in Q1 2025.
• The auditor's report indicates substantial doubt about the company's ability to continue as a going concern due to recurring losses and a net capital deficiency.
• Total revenues decreased by 13% year-over-year in 2024 and by 69% in Q1 2025 compared to Q1 2024, primarily due to a decline in U.S. and foreign sales.
• Gross profit turned into a gross loss of $(358) thousand in Q1 2025, compared to a gross profit of $807 thousand in Q1 2024.
• The company has a significant working capital deficit, reaching $(30.435) million as of March 31, 2025.
• Total liabilities have significantly increased from $14.926 million in 2023 to $40.620 million in Q1 2025.
• There is high customer concentration, with Customer A accounting for 49% of Q1 2025 revenue and 70% of Q1 2024 revenue.
• The company relies on specialized single-source suppliers (Bimba/Heitek Automation) for crucial driver components and does not have second-source suppliers for many components, posing supply chain risks.
• The EU CE mark for the SynCardia TAH was voluntarily cancelled in July 2022 due to post-market surveillance deficiencies, limiting sales in European markets until MDR CE mark reapplication (planned Q4 2025).
• 104 reports of cannula tears have been received as of March 20, 2025, indicating a product deficiency, although no Serious Adverse Events have been reported.
• The company owes approximately $492,000 in outstanding royalty payments to Medtronic for an expired license agreement, with Medtronic holding a security interest that could be foreclosed upon.
• Several related party convertible notes are past due, and the company is working with lenders to extend maturity dates.
• The company does not intend to pay cash dividends for the foreseeable future, retaining earnings for operations and growth.
• The company will be a 'controlled company' after the IPO, relying on exemptions from certain NYSE American corporate governance standards, which may reduce protections for stockholders.
• The regulatory approval processes for new products and expanded indications are lengthy, time-consuming, and inherently unpredictable, with no guarantee of approval on expected timelines or at all.

Risks

• History of significant losses and inability to achieve and sustain profitability, leading to substantial doubt about continuing as a going concern.
• Inability to manufacture the SynCardia TAH on a timely basis consistent with quality standards due to specialized knowledge and operator skills.
• Reliance on specialized single-source suppliers for critical components, with limited or no second-source options, risking production delays.
• Significant customer concentrations and lack of long-term exclusive agreements with customers, leading to potential revenue fluctuations.
• Future success depends on timely development, regulatory approval (including long-term indication), and market acceptance of new products or enhancements.
• Inability to successfully complete pre-clinical studies or clinical trials necessary for regulatory approvals of novel products.
• Inadequate third-party payor coverage and reimbursement for products, impacting market adoption and revenues.
• Changes in U.S. and international trade policies, particularly with respect to China, adversely impacting business and operating results.
• Need to undertake additional clinical trials to secure FDA expansion of SynCardia TAH indication from Bridge-to-Transplant (BTT) to Long-Term (LT).
• Failure to reinstate the CE certificate under CE MDR could materially adversely affect business in European markets.
• Prior weaknesses in compliance with post-market surveillance requirements under CE MDD may limit ability to market or sell products in European markets.
• Many aspects of the SynCardia TAH are no longer protected by patents, increasing vulnerability to competition if trade secrets are misappropriated or become publicly known.
• Exposure to extensive patent and other intellectual property litigation in the medical device industry, potentially leading to costly disputes, damages, or inability to market products.
• Cessation of commercial ties or contractual arrangements with Bimba or Heitek Automation, sole source suppliers for crucial driver components, could negatively impact business.
• Share price volatility due to various factors, including operating performance, competitive landscape, regulatory developments, and general market conditions.
• Classification as an emerging growth company and smaller reporting company may make securities less attractive to investors due to reduced disclosure requirements.
• No intention to pay cash dividends for the foreseeable future, limiting investor returns.
• Future sales of common stock, or the perception of such sales, may cause the market price to decline.
• Increased costs and demands upon management as a result of complying with laws and regulations affecting public companies.
• Potential for securities class action or derivative litigation.
• Inability to implement and maintain effective internal control over financial reporting, leading to loss of investor confidence.
• Lack of prior public market for common stock, with potential for price decline after the offering.
• Significant dilution to stockholders upon conversion of Series A-1 Preferred Shares and certain related party loans.
• Risk of an inactive trading market for common stock.
• Reliance on controlled company corporate governance exemptions, potentially reducing protections for stockholders.
• Exclusive forum provisions in the company's charter could limit stockholders' ability to bring claims in preferred judicial forums.
• Off-label use or misuse of products could harm reputation, lead to product liability suits, or regulatory sanctions.
• Compliance with medical device reporting (MDR) requirements and potential for voluntary corrective actions or agency enforcement actions.
• Risk of employee misconduct or other improper activities, including non-compliance with regulatory standards and healthcare fraud laws.
• Exposure to various federal, state, and foreign healthcare laws and regulations, with potential for significant penalties for non-compliance.
• Risks associated with acquiring other companies or businesses, including integration difficulties and failure to achieve anticipated synergies.
• Failure to protect information technology infrastructure against cyber-based attacks, network security breaches, or data corruption.
• Demand for total artificial hearts depends on various factors, including medical advances that could provide better alternatives or replace TAH use.

Future Outlook

Picard Medical's future vision is to develop the world's first fully implantable SynCardia TAH, 'Emperor', as an alternative to heart transplantation, with acute animal studies planned for the second half of 2025 and potential FDA approval by 2028. The company is committed to innovating its current driver technology, with FDA approval for the upgraded 'Freedom+' driver expected in late 2026 and next-generation Freedom and C2 Drivers expected in the second halves of 2026 and 2027, respectively. They also plan to expand the SynCardia TAH's indication for use from Bridge to Transplantation (BTT) to Bridge to Candidacy (BTC) and for long-term use of two years or more, with an FDA answer on the BTC and 'imminent death' removal submission expected in Q2 2026. International expansion is a key driver, with efforts underway to reapply for an MDR CE mark in the EU during Q4 2025, seek NMPA approval in China within 12 months from filing, and pursue market entry in India and the Middle East.

Management Comments

• Management believes that based on their technology, intellectual property, know-how, and extensive human clinical experience, they have significant advantages over other companies developing other TAH products.
• Management believes that the trade secrets protecting their proprietary Segmented Polyurethane Solution (SPUS) and its biocompatibility are likely to present a major barrier to any potential competitor using similar material.
• Management believes that they maintain a strong position among peers in the total artificial heart category due to their track record, regulatory approvals, manufacturing processes, sales and marketing expertise, and long-term reputation for quality.
• Management acknowledges that the regulatory approval processes of the FDA are lengthy, time-consuming, and inherently unpredictable, with no guarantee of receiving approval on expected timelines or at all.
• Management expects to continue to incur significant expenses and operating losses for the foreseeable future as they expand sales and marketing, increase manufacturing, pursue additional regulatory approvals, and continue R&D activities.
• Management expects to raise sufficient cash to fund operations into 2025 based on their current business plan, expectations, and assumptions considering current macroeconomic conditions, but notes these plans have not been finalized and there is no assurance of success in raising cash from the IPO.

Industry Context

Cardiovascular disease is the leading cause of death globally, with 6.8 million people suffering from heart failure in the U.S. and 56.2 million worldwide. Heart transplantation is the treatment of choice for advanced heart failure, but demand for donor hearts significantly exceeds supply, with over 7,500 patients on the U.S. transplant list and only 4,539 transplants performed in 2023. This unmet need creates a market for total artificial hearts like SynCardia TAH. The global market for heart implants is substantial, with estimated millions of heart failure patients in the EU, India, China, and the Middle East. The company faces competition from alternative, often less expensive, therapies like Left Ventricular Assist Devices (LVADs) and other TAH manufacturers such as Carmat SA (which recently filed for insolvency) and BiVACOR, Inc. (in early-stage human clinical testing).

Comparison to Industry Standards

• **SynCardia TAH (Picard Medical):** Only U.S. FDA and Health Canada approved artificial heart for BTT. Ventricle blood volume: 50cc and 70cc, serving men, women, and children. Total implant size (volume): 250-400ml. Number of implants: More than 2,100 as of March 2025. Implant weight: 250g. Has extensive human clinical experience and proprietary SPUS material.
• **Carmat (Aeson):** Approved in the EU (CE mark in 2020 under MDD), but recently filed for insolvency in France (June 30, 2025) and is in receivership. Ventricle blood volume: 65cc, which 'may not fit women, children, and smaller-built men'. Total implant size (volume): 750ml. Number of implants: 108 as of February 2025. Implant weight: 900g. Has experienced quality and software issues, recommending natural heart transplant as soon as possible.
• **BiVACOR:** Completed first 5 patients of 20 to be enrolled in Early Feasibility Study (EFS) in the U.S. (started July 2024). One patient implanted in Australia. Not yet approved for commercial use in any market. Total implant size (volume): 400ml. Number of implants: Six as of March 2024. Implant weight: 650g.
• **Abbott HeartMate 3 (LVADs):** Cardiologists explore simultaneous use of two LVADs ('HeartMate 6') for biventricular assistance, but this practice is not FDA approved. LVADs are approved for long-term use and support only the left ventricle. Reimbursed under DRG 001, similar to SynCardia TAH, with payments ranging from $193,000 to $469,000. Average selling price around $120,000.
• **Temporary MCS (e.g., ECMO, axial flow LVADs):** Support left or right ventricle only, for hospital use only (not for discharge), and should not be used for more than two weeks. ECMO reimbursed under DRG 003 (average $170,000), axial flow devices under DRG 215 or 221 (average $90,000 and $40,000). Average selling price for Abiomed Impella 2.5/5.0 is $20,000-$30,000, and Getinge CardioHelp (ECMO) is around $111,000.

Corporate Governance

Legal Proceedings

• As of the date of this prospectus, the company is not a party to any material legal matters or claims.
• The company may become party to legal matters and claims in the ordinary course of business in the future, but does not anticipate that their resolution would have a material adverse impact on its financial position, results of operations, or cash flows.

Related Party Transactions

• As of July 9, 2025, the company has numerous outstanding related party or affiliated loans in the form of working capital loans and convertible notes, primarily from Hunniwell and Fang Family Funds (entities affiliated with executive directors).
• A $7.0 million aggregated convertible note from Richard Fang and Fang Family Funds, dated July 2, 2024, was donated to unrelated not-for-profit organizations (Nexus Science Foundation Inc. and Another Dimension Foundation) on November 12, 2024, and is subject to automatic conversion into common stock at a 50% discount to the IPO price upon an IPO.
• On July 2, 2023, Picard Medical, Inc. agreed to invest $2.85 million for a 60% ownership interest in SynCardia Medical (Beijing), Inc., contingent on becoming publicly traded on a stock exchange. This will make SynCardia Medical (Beijing), Inc. a majority-owned subsidiary.
• On July 1, 2025, the company amended a $250,000 related party working capital loan and issued new loans of $93,633 to Hunniwell (for travel expense reimbursements) and $187,190 to Daniel Teo (for severance from prior employment) under the terms of the Senior Secured Notes, with a modified maturity date of October 15, 2025.
• On July 8, 2025, the company borrowed $425,000 from Fang Family Fund I, LLC, due October 15, 2025, under the same Senior Secured Notes terms.
• The company has an outstanding unsecured promissory note of $112,000 (including accrued interest) from Versa Capital Management, LLC (a related party) as of March 31, 2025, which has not been collected.
• In March 2025, the company issued 352,852 shares of common stock for $500,000 to certain investors, and in April 2025, issued 695,277 shares for $1.0 million, some of which may be related parties.
• On July 7, 2025, Hunniwell exercised its option to convert all of its preferred stock into 39,618,919 shares of common stock.

Stakeholder Impact

• **Shareholders:** Will experience significant dilution from the IPO and the conversion of preferred shares and convertible notes. Existing shareholders will see their ownership interest immediately diluted. The stock price is expected to be volatile, and there is no intention to pay cash dividends in the foreseeable future. The 'controlled company' status may limit shareholder influence on corporate governance.
• **Employees:** The company's 'going concern' doubt and recurring losses could impact job security and future compensation, despite management's stated human capital objectives to attract and retain talent.
• **Customers (Hospitals/Surgeons):** Product availability could be impacted by supply chain issues (single-source suppliers) or manufacturing delays. Quality issues like cannula tears, though not serious adverse events, require attention and may affect confidence. Regulatory changes (e.g., EU CE mark reapplication) could affect product access in certain markets.
• **Suppliers:** Reliance on single-source suppliers like Bimba/Heitek Automation creates a critical dependency, and any cessation of ties could disrupt the company's ability to produce drivers.
• **Creditors:** The company's significant debt, including past-due convertible notes and related party loans, indicates high credit risk. The security interests granted to lenders on company assets could impact other creditors in case of financial distress.

Next Steps

• Complete the Initial Public Offering and list shares on the NYSE American under the symbol PMI.
• Fund SynCardia Medical (Beijing), Inc. with $2.85 million to support market expansion in China, contingent on the IPO.
• Continue research and development activities for the fully implantable 'Emperor' TAH, with acute animal studies planned for H2 2025 and potential FDA approval by 2028.
• Pursue FDA approval for the upgraded 'Freedom+' portable driver system, anticipated by H2 2025.
• Develop and seek FDA approvals for next-generation Freedom and C2 Drivers, expected in H2 2026 and H2 2027, respectively.
• Obtain FDA approval for expanded SynCardia TAH indications (Bridge to Candidacy and long-term use), with an answer expected in Q2 2026 for the current submission.
• Complete validation activities and submit a design change to the FDA for cannula tears in approximately Q3 2025.
• Reapply for an MDR CE mark in the EU during Q4 2025 to regain market access.
• Continue efforts to enter the Indian market through MD-15 license filing and individual patient licenses.
• Seek a local distribution partner for the Middle East and pursue regulatory approvals in other strategic international markets.
• Repay or convert outstanding related party loans and convertible notes, including those that are past due.
• Implement and maintain effective internal control over financial reporting as a public company.

Key Dates

Recommendation

Keywords

Total Artificial Heart, SynCardia TAH, Medical Device, Heart Failure, IPO, FDA Approval, CE Mark, Medical Technology, Cardiovascular, Implantable Device, Bridge to Transplant, Bridge to Candidacy, Emperor TAH, Freedom Driver, Pneumatic Driver, Biomedical Engineering, Healthcare Industry, SEC Filing, S-1/A